Zacks Research Analysts Decrease Earnings Estimates for CRSP

CRISPR Therapeutics AG (NASDAQ:CRSP) – Equities researchers at Zacks Research cut their Q2 2025 earnings per share (EPS) estimates for shares of CRISPR Therapeutics in a report released on Monday, December 9th. Zacks Research analyst R. Department now anticipates that the company will post earnings of ($1.48) per share for the quarter, down from their previous forecast of ($1.47). The consensus estimate for CRISPR Therapeutics’ current full-year earnings is ($5.13) per share. Zacks Research also issued estimates for CRISPR Therapeutics’ Q3 2025 earnings at ($1.39) EPS, Q4 2025 earnings at ($1.32) EPS, FY2025 earnings at ($5.70) EPS, Q1 2026 earnings at ($1.40) EPS, Q2 2026 earnings at ($1.11) EPS, Q3 2026 earnings at ($0.60) EPS and FY2026 earnings at ($3.44) EPS.

CRISPR Therapeutics (NASDAQ:CRSP) last released its quarterly earnings results on Tuesday, November 5th. The company reported ($1.01) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.42) by $0.41. The company had revenue of $0.60 million during the quarter, compared to analysts’ expectations of $6.65 million. CRISPR Therapeutics had a negative return on equity of 12.15% and a negative net margin of 118.13%. During the same period in the previous year, the firm posted ($1.41) earnings per share.

A number of other equities analysts have also weighed in on the stock. Royal Bank of Canada reissued a “sector perform” rating and issued a $53.00 price objective on shares of CRISPR Therapeutics in a research report on Wednesday, November 6th. Needham & Company LLC reiterated a “buy” rating and issued a $84.00 price target on shares of CRISPR Therapeutics in a report on Wednesday, November 6th. StockNews.com raised CRISPR Therapeutics to a “sell” rating in a research note on Wednesday. Barclays lowered their price objective on CRISPR Therapeutics from $59.00 to $55.00 and set an “equal weight” rating for the company in a research report on Wednesday, November 6th. Finally, Chardan Capital reiterated a “buy” rating and set a $94.00 target price on shares of CRISPR Therapeutics in a research report on Tuesday. Two research analysts have rated the stock with a sell rating, eight have given a hold rating and nine have assigned a buy rating to the stock. Based on data from MarketBeat.com, CRISPR Therapeutics currently has an average rating of “Hold” and a consensus price target of $77.93.

CRISPR Therapeutics Trading Down 3.6 %

Shares of CRSP stock opened at $43.78 on Thursday. CRISPR Therapeutics has a twelve month low of $42.86 and a twelve month high of $91.10. The company has a market capitalization of $3.74 billion, a price-to-earnings ratio of -15.47 and a beta of 1.62. The firm has a 50-day moving average price of $48.79 and a 200 day moving average price of $51.21.

Insider Buying and Selling

In other news, CEO Samarth Kulkarni sold 30,000 shares of the company’s stock in a transaction on Monday, November 11th. The shares were sold at an average price of $55.62, for a total value of $1,668,600.00. Following the completion of the transaction, the chief executive officer now directly owns 196,540 shares in the company, valued at approximately $10,931,554.80. This represents a 13.24 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, General Counsel James R. Kasinger sold 1,089 shares of CRISPR Therapeutics stock in a transaction on Monday, October 14th. The stock was sold at an average price of $46.28, for a total transaction of $50,398.92. Following the sale, the general counsel now directly owns 62,597 shares in the company, valued at $2,896,989.16. This trade represents a 1.71 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 50,382 shares of company stock valued at $2,744,179. Company insiders own 4.10% of the company’s stock.

Hedge Funds Weigh In On CRISPR Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in CRSP. Larson Financial Group LLC grew its stake in CRISPR Therapeutics by 95.5% during the 2nd quarter. Larson Financial Group LLC now owns 565 shares of the company’s stock valued at $31,000 after purchasing an additional 276 shares in the last quarter. GPS Wealth Strategies Group LLC grew its holdings in CRISPR Therapeutics by 99.7% during the 2nd quarter. GPS Wealth Strategies Group LLC now owns 615 shares of the company’s stock worth $33,000 after acquiring an additional 307 shares in the last quarter. Itau Unibanco Holding S.A. bought a new stake in shares of CRISPR Therapeutics in the 2nd quarter worth about $35,000. Wilmington Savings Fund Society FSB acquired a new stake in shares of CRISPR Therapeutics in the 3rd quarter valued at about $40,000. Finally, Darwin Wealth Management LLC bought a new position in shares of CRISPR Therapeutics during the third quarter worth about $43,000. 69.20% of the stock is owned by hedge funds and other institutional investors.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.